Enveric Biosciences (ENVB) Prepaid Assets (2011 - 2026)
Enveric Biosciences (ENVB) posted Prepaid Assets of $5478.0 for Q1 2026, down 92.9% sequentially from $77179.0 in Q4 2025, and down 93.9% YoY from $89762.0 in Q1 2025.
Enveric Biosciences (ENVB) Prepaid Assets (2011 - 2026) Analysis & Trends
Enveric Biosciences has reported Prepaid Assets for 16 years, with the latest figure at $5478.0 in Q1 2026.
- Quarterly Prepaid Assets fell 93.9% year-over-year to $5478.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5478.0 (down 93.9% YoY) and the FY2025 annual result came in at $77179.0, down 49.52% from the prior year.
- Prepaid Assets slipped to $5478.0 in Q1 2026 per ENVB's latest filing, from $77179.0 in the prior quarter.
- Over five years, Prepaid Assets peaked at $2.3 million in Q1 2023 and troughed at $3156.0 in Q2 2025.
- A 5-year average of $542997.9 and a median of $222330.0 in 2023 frame the typical range for Prepaid Assets.
- The sharpest annual moves came in 2023 and 2025: Prepaid Assets soared 134.54% in 2023, then plunged 98.69% in 2025.
- Over 5 years, Prepaid Assets stood at $159782.0 in 2022, then slipped by 6.4% to $149559.0 in 2023, then grew by 2.23% to $152894.0 in 2024, then plunged by 49.52% to $77179.0 in 2025, then plunged by 92.9% to $5478.0 in 2026.
- According to Business Quant data, Prepaid Assets over the past three periods registered $5478.0, $77179.0, and $4082.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.81 Bn | 130.96 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 86.07 Bn | 78.08 Bn | 3.93 Bn |
| 3 | Argenx Se | 65.47 Bn | 60.29 Bn | 1.37 Bn |
| 4 | Moderna | 55.64 Bn | 50.50 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.99 Bn | 36.89 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.68 Bn | 28.37 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.69 Bn | 9.29 Bn | 668.28 Mn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.36 Bn | 26.52 Bn | - |
| 10 | Enveric Biosciences | 5.72 Mn | -2.57 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 5,478.00 |
| Dec 31, 2025 | 77,179.00 |
| Sep 30, 2025 | 4,082.00 |
| Jun 30, 2025 | 3,156.00 |
| Mar 31, 2025 | 89,762.00 |
| Dec 31, 2024 | 152,894.00 |
| Sep 30, 2024 | 245,972.00 |
| Jun 30, 2024 | 241,269.00 |
| Mar 31, 2024 | 1.87 Mn |
| Dec 31, 2023 | 149,559.00 |
| Sep 30, 2023 | 332,508.00 |
| Jun 30, 2023 | 222,330.00 |
| Mar 31, 2023 | 2.28 Mn |
| Dec 31, 2022 | 159,782.00 |
| Sep 30, 2022 | 1.07 Mn |
| Jun 30, 2022 | 1.36 Mn |
| Mar 31, 2022 | 970,899.00 |
| Dec 31, 2021 | 380,838.00 |
| Sep 30, 2021 | 833,116.00 |
| Jun 30, 2021 | 891,467.00 |